Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lumos Pharma Inc LUMO

Healthcare Biotechnology
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing its clinical program and focused on identifying, acquiring, developing, and commercializing products and new therapies for people with rare diseases. Its pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also... see more

Recent & Breaking News (NDAQ:LUMO)

Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results

GlobeNewswire 4 days ago

Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024

GlobeNewswire 9 days ago

Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings

GlobeNewswire April 18, 2024

Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042

GlobeNewswire March 20, 2024

Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update

GlobeNewswire March 7, 2024

Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024

GlobeNewswire February 26, 2024

Lumos Pharma to Participate in Oppenheimer's 34th Annual Healthcare Life Sciences Conference

GlobeNewswire February 5, 2024

Lumos Pharma Promotes Pisit "Duke" Pitukcheewanont, MD to Chief Medical Officer

GlobeNewswire January 4, 2024

Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency

GlobeNewswire November 21, 2023

Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November

GlobeNewswire November 20, 2023

Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates

GlobeNewswire November 7, 2023

Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints

GlobeNewswire November 7, 2023

Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting

GlobeNewswire September 26, 2023

Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting

GlobeNewswire September 14, 2023

Lumos Pharma Announces Participation in Investor Conferences in September

GlobeNewswire September 7, 2023

Independent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic Landscape

GlobeNewswire August 22, 2023

Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update

GlobeNewswire August 9, 2023

Lumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023

GlobeNewswire July 26, 2023

Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences Summit

GlobeNewswire July 12, 2023

Lumos Pharma Announces Departure of Chief Medical Officer

GlobeNewswire June 28, 2023